ReviewCurrent opinion in urology2017
The role of prostate cancer biomarkers in undiagnosed men.
Review in Current opinion in urology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 22 citations in OpenAlex.
- Enhancing prostate cancer diagnosis: a machine learning-based biomarker approach.Human genomics · 2026Article
- Can the predictive value of multiparametric MRI for prostate cancer be improved by a liquid biopsy with SelectMDx?Cancer reports (Hoboken, N.J.) · 2021Article
- Exosomes as A Next-Generation Diagnostic and Therapeutic Tool in Prostate Cancer.International journal of molecular sciences · 2021Review
- Magnetic Resonance Imaging (MRI)-Targeted Biopsy in Patients with Prostate-Specific Antigen (PSA) Levels <20 ng/mL: A Single-Center Study in Northeastern China.Medical science monitor : international medical journal of experimental and clinical research · 2021Observational
- Cancer diagnostics based on plasma protein biomarkers: hard times but great expectations.Molecular oncology · 2021Review
- Proteomic Tissue-Based Classifier for Early Prediction of Prostate Cancer Progression.Cancers · 2020Article
- Optimal threshold of the prostate health index in predicting aggressive prostate cancer using predefined cost-benefit ratios and prevalence.International urology and nephrology · 2020Article
- Relationship of Total and Free 25-Hydroxyvitamin D to Biomarkers and Metabolic Indices in Healthy Children.The Journal of clinical endocrinology and metabolism · 2020Article
- Prediction Medicine: Biomarkers, Risk Calculators and Magnetic Resonance Imaging as Risk Stratification Tools in Prostate Cancer Diagnosis.International journal of molecular sciences · 2019Review
- N-Linked Glycosylation and Near-Infrared Spectroscopy in the Diagnosis of Prostate Cancer.International journal of molecular sciences · 2019Article
- Future Perspectives and Challenges of Prostate MR Imaging.Radiologic clinics of North America · 2018Review
- Advances in Biomarkers for PCa Diagnostics and Prognostics-A Way towards Personalized Medicine.International journal of molecular sciences · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewThis article intends to review biomarkers derived from blood, urine, and tissue that can aid in the diagnosis of prostate cancer (PCa). RECENT
findingsPCa screening requires tools that complement prostate-specific antigen (PSA) with a higher specificity for clinically significant disease. Novel blood biomarkers, such as the Prostate Health Index (phi) and 4Kscore, utilize isoforms of PSA to more accurately predict high-grade PCa than traditional tools such as PSA and the percentage free-to-total PSA. Several gene products associated with PCa can be detected in the urine through commercially available assays. PCa antigen 3 (PCA3), though approved for repeat biopsy decisions, appears inferior to other biomarkers such as phi for identifying aggressive disease. However, combinations of PCA3 with other urine assays have shown promising results. One tissue-based hypermethylation test, named ConfirmMDx, can also be used to determine the need for repeat biopsy in men with a prior negative biopsy. SUMMARY: Several biomarkers have been developed to aid in the screening and diagnosis of PCa. Such tests are often indicated in men with moderately elevated PSA or history of a prior negative biopsy. Their use facilitates reduction of unnecessary biopsies without sacrificing the early diagnosis of clinically significant PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.